Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

commercial value of our innovative cold sore product Xerclear(R)/Xerese(R ) and have signed two further agreements in different geographic markets.

The success demonstrated with Xerclear(R) and Xerese(R) shows Medivir's ability to develop and commercialize products and collaborate with blue-chip partners.

Following the successful rights issue concluded in June 2010 we are in healthy financial position and have therefore been able to remain focused on developing our exciting portfolio of early-phase projects for infectious diseases.

Medivir is positioned uniquely among specialty pharmaceutical companies with a potential blockbuster Hepatitis C therapy in late-stage development, a marketed product, Xerclear(R)/Xerese(R), approaching international launch, a broad earlier pipeline and a solid financial position. Medivir will now remain focused on creating further shareholder value and continues to gain momentum in its strategic goal to become a profitable specialty pharmaceutical company. We look forward to sharing our exciting future news flow going forward with both our patients and our shareholders as we continue to build the growth in this business."

For the full Q3 report please visit http://www.medivir.se. For more information, please contact Rein Piir, CFO and VP, Investor Relations, mobile: +46(0)70-853-7292. Ron Long, CEO, phone: +46(0)8-5468-3113. Forthcoming financial information and calendar Financial Statement will be published on 22 February 2011. Three-month Interim Report will be published on 5 May 2011. Annual General Meeting will be held on 5 May 2011.

Additional information on Medivir's operations is available on the company's website, http://www.medivir.se.


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Testing Market"  report to their offering.  ... ,This comprehensive five-country report contains 500 pages, ... current suppliers and potential market entrants identify ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market ... is an autoimmune disease that permanently destroys beta cells of ... longer produce insulin. Over the last 90 years, insulin therapy ... can be offered to a patient who is newly diagnosed ... of action - long-acting as well as short or rapid-acting ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... CITY, Calif., July 7 Relievant Medsystems, Inc., developer ... back pain, reported today that it has completed a ... led by Morgenthaler Ventures with existing investors Canaan Partners ... participating. The company also announced that Morgenthaler partner ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin ... published on-line in Diabetologia ... in the two treatment groups. This is the longest controlled ...
Cached Medicine Technology:Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 45-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 5
(Date:5/28/2015)... The Cancer Solution: Taking Charge of Your ... and heartfelt book the Booksandauthor reviewer ever read ... for writing what should be one of the most important ... is power in action and this book has both. , ... talk about and unfortunately many persons know little about it. ...
(Date:5/28/2015)... 2015 The 110-mile April 24-26 ... from national non-profit World T.E.A.M. Sports is featured in ... With Heroes . , Host Bob Calvert and videographers ... and civilian riders, sponsors and staff members. The April ... a musical performance by The American Bombshells and a ...
(Date:5/27/2015)... (PRWEB) May 28, 2015 Calls Upon Individuals, ... , A new nationwide initiative – a “Summer of Service” ... create and build partnerships to grow the number of individuals ... renewing its commitment to Veterans by inviting the community to ... house June 29, 2015 from 1 – 3:00 p.m. in ...
(Date:5/27/2015)... is a reputable source of 2015 NHL Western Conference Finals ... of their series against the Anaheim Ducks with the Ducks currently ... win tonight at home, this will tie up the series with ... Center in Anaheim. , During the regular season, the Ducks ... won the Pacific Division by 8 points ahead of the second ...
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
Breaking Medicine News(10 mins):Health News:Booksandauthor Cites The Cancer Solution as One of the Most Important Books to Read 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 3Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2
... for Prescription Prenatal Vitamins , , ... once-daily prescription prenatal vitamin in its category, delivering the most ... ST. LOUIS, Dec. 17 KV Pharmaceutical Company (NYSE: ... - the U.S. market leader in branded prenatal vitamins ...
... Mass., Dec. 17 Biopure Corporation (Nasdaq: ... the Food and Drug Administration (FDA) an investigational new ... 2 clinical trial of the company,s oxygen therapeutic Hemopure(R) ... trial Hemopure would be studied for use ...
... Closed the Amendment of the , -------------------------------------------------------------------- ... Notes , ------------------------------------------------- , ... BELLUS Health Inc. (NASDAQ: BLUS ; TSX: ... the NASDAQ Stock Market of its intention to voluntarily ...
... leaders pay tribute to Africa Mercy crew and commit to continue progress. ... and general Mercy Ships footage are available for download with registration at ... ... 2008 -- The Africa Mercy pulled out of the Free ...
... and B2B Marketing Pro Toby Younis today announced a free webcast ... The webcast is designed for executives in B2B companies facing challenging ... ... DC (PRWEB) December 17, 2008-- Widely recognized B2B marketing expert ...
... Physician Hospitals of America (PHA) is applauding President-elect Barack Obama,s ... Department of Health and Human Services in his Cabinet. , ... U.S. Senator from South Dakota, is both known and respected ... Falls. , , "Tom Daschle ...
Cached Medicine News:Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 3Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 4Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 5Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 2Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 3Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 2Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 3Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 3Health News:B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking" 2Health News:Physician Hospitals of America (PHA) Applauds President-Elect Obama's Selection of Sen. Daschle as HHS Secretary 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... DIFF CHEK-30 is a rapid ELISA ... 100% negative predictive value and 99% sensitivity. ... and cost-effectively screen out C. difficile negatives ... of samples - before culturing for the ...
Medicine Products: